olivLaw · US equity research
Endovia Health Sciences, Inc. EDVA
Beverages · SIC 2080 · Vertical: Beverages (SIC 2080)
Endovia Health Sciences (formerly Splash Beverage Group) is moving from alcoholic beverages to a cannabinoid-based health sciences platform after sales effectively stopped in 2025. Net revenue of about 0.44 million USD in fiscal 2025 and a net loss of about 25.2 million USD show the scale of the liquidity problems the company is trying to overcome.
At the close of 04 Nov 2026, Endovia Health Sciences, Inc. (EDVA) stock was 0.19 USD (+2.94% on the day), with market capitalisation 1.2 m USD, beta 1.40, 52-week range 0.14–6.00 USD. Latest reported quarter (Q2 2026): revenue of 0 USD, net income of -2.1 m USD, diluted EPS -0.67 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 53.9
- neutral
- Bollinger (20, 2)
- 0.13 – 0.19
- in the upper half of the band · %B 1.00 · band width 35.4%
- SMA 50 / 200
- 0.20 / 1.06
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.01 / -0.02
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +11.6% | −1.1% | +12.7 pp | — |
| 3 months | −56.4% | −0.5% | −55.9 pp | — |
| 6 months | −81.5% | +4.4% | −85.9 pp | — |
| Year to date | −93.3% | +12.3% | −105.6 pp | — |
| 1 year | −96.5% | +13.5% | −110.0 pp | +6.7% |
| 3 years | −99.8% | +76.4% | −176.2 pp | −22.9% |
| 5 years | −99.9% | +63.7% | −163.6 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 981.9 k | -2.8 m | 68.6 k | -23.4 k ≈ | 393.1 k ≈ | -365.2 k | 4.2 k | 0 ≈ |
| Cost of revenue | 690.8 k | 929.5 k | 468.7 k | 0 ≈ | 0 ≈ | — | — | — |
| Gross profit | 291.0 k | -818.9 k | 25.5 k | -32.1 k ≈ | -23.8 k ≈ | 47.3 k | 1.8 k | 0 ≈ |
| Operating income | -2.7 m | -289.6 k | -1.7 m | -1.5 m | -9.5 m | -976.4 k | -979.0 k | -2.0 m |
| Depreciation & amortisation | 135.1 k ≈ | -3.7 k | 2.3 k | 2.3 k ≈ | 106.4 k ≈ | -101.8 k | 2.3 k | — |
| Interest expense | 890.5 k | 1.7 m | 637.3 k | 625.0 k | 320.0 k | 940.9 k | 889.5 k | 231.0 k |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -4.7 m | -9.0 m | -3.7 m | -8.5 m | -9.9 m | -3.2 m | -2.1 m | -2.1 m |
| Diluted EPS | -3.61 ≈ | -6.03 ≈ | -1.97 | -17.88 ≈ | -4.51 ≈ | -1.15 ≈ | -0.47 | -0.67 ≈ |
| Operating cash flow | -2.6 m ≈ | -919.7 k | -808.0 k | -551.1 k ≈ | -2.5 m ≈ | -991.2 k | -930.5 k | -1.1 m ≈ |
| Capex | — | 0 | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | ⚠ 2019 | 2020 | 2021 | 2022 | 2023 | ⚠ 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3 m | 20.4 k | 2.3 m | 11.3 m | 18.1 m | 18.9 m | 801.3 k | 73.1 k |
| Revenue YoY | +46.2% | — | +11,182.3% | +392.0% | +59.8% | +4.2% | — | −90.9% |
| Net income | 68.2 k | -5.1 m | -28.7 m | -29.1 m | -21.7 m | -21.0 m | -23.8 m | -25.2 m |
| Net income YoY | unavailable | — | unavailable | unavailable | unavailable | unavailable | — | unavailable |
| Diluted EPS | 0.01 | -0.04 | -1.06 | -1.02 | unavailable | unavailable | -17.68 | -11.97 |
| Diluted EPS YoY | unavailable | — | unavailable | unavailable | unavailable | unavailable | — | unavailable |
| net % | 5.2% | -25,191.2% | -1,246.7% | -256.7% | -119.9% | -111.4% | -2,964.9% | -34,537.0% |
| Free cash flow | -13.2 k | -2.7 m | -21.4 m | -14.7 m | -14.1 m | -10.2 m | -7.3 m | unavailable |
The series breaks before 2019, 2024: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 281.4 k USD
- Financial debt
- 3.4 k USD
- Net debt
- -278.0 k USD
- Equity
- -15.3 m USD
- Total assets
- 965.7 k USD
- Debt / equity
- unavailable
- Current ratio
- 0.04x
- ROE
- unavailable
- ROA
- -1,354.9%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 2.3 m | 11.3 m | 18.1 m | 18.9 m | 801.3 k | 73.1 k | SEC (XBRL)· 15 Apr 2026verified |
| Cost of revenue | 1.9 m | 7.4 m | 12.2 m | 13.3 m | 3.8 m | — | SEC (XBRL)· 11 Jul 2025verified |
| Gross profit | 363.6 k | 3.9 m | 5.9 m | 5.6 m | -119.8 k | 16.9 k | SEC (XBRL)· 15 Apr 2026verified |
| Operating income | -17.7 m | -29.1 m | -21.4 m | -15.3 m | -9.9 m | -14.2 m | SEC (XBRL)· 15 Apr 2026verified |
| Depreciation & amortisation | 113.3 k | 111.6 k | 936.0 k | 546.0 k | 401.6 k | 9.3 k | SEC (XBRL)· 15 Apr 2026verified |
| EBITDA | -17.5 m ≈ | -29.0 m ≈ | -20.5 m ≈ | -14.7 m ≈ | -9.5 m ≈ | -14.2 m ≈ | SEC (XBRL)· 15 Apr 2026derived |
| Interest expense | — | 442.8 k | 251.5 k | 1.9 m | 3.7 m | 2.5 m | SEC (XBRL)· 15 Apr 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 15 Apr 2026verified |
| Net income | -28.7 m | -29.1 m | -21.7 m | -21.0 m | -23.8 m | -25.2 m | SEC (XBRL)· 15 Apr 2026verified |
| Diluted EPS | -1.06 | -1.02 | — | — | -17.68 | -11.97 | SEC (XBRL)· 15 Apr 2026verified |
| Weighted average diluted shares | 18.5 m | 28.9 m | 37.4 m | 1.1 m | 1.3 m | 2.2 m | SEC (XBRL)· 15 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 380.0 k | 4.2 m | 4.4 m | 380.0 k | 13.8 k | 281.4 k | SEC (XBRL)· 15 Apr 2026verified |
| Receivables | 484.9 k | 1.1 m | 1.8 m | 890.6 k | 192.0 k | 15.7 k | SEC (XBRL)· 15 Apr 2026verified |
| Inventories | 798.3 k | 1.9 m | 3.7 m | 2.3 m | 319.1 k | 33.5 k | SEC (XBRL)· 15 Apr 2026verified |
| Current assets | 2.2 m | 8.3 m | 10.7 m | 4.0 m | 1.9 m | 632.0 k | SEC (XBRL)· 15 Apr 2026verified |
| Property, plant & equipment, net | 681.4 k | 569.8 k | 489.6 k | 349.8 k | 22.2 k | 12.9 k | SEC (XBRL)· 15 Apr 2026verified |
| Goodwill | 5.7 m | 256.8 k | 256.8 k | 256.8 k | — | — | SEC (XBRL)· 29 Mar 2024verified |
| Intangibles (excl. goodwill) | — | 5.6 m | 4.9 m | 4.5 m | — | — | SEC (XBRL)· 29 Mar 2024verified |
| Total assets | 9.2 m | 16.4 m | 17.3 m | 9.9 m | 2.8 m | 965.7 k | SEC (XBRL)· 15 Apr 2026verified |
| Accounts payable | 1.5 m | 1.9 m | 3.4 m | 4.4 m | 3.6 m | 4.8 m | SEC (XBRL)· 15 Apr 2026verified |
| Long-term debt | 1.2 m | 0 | 2.5 m | 457.7 k | 2.0 m | 3.4 k | SEC (XBRL)· 15 Apr 2026verified |
| Current liabilities | 5.4 m | 6.5 m | 5.0 m | 14.8 m | 19.4 m | 16.3 m | SEC (XBRL)· 15 Apr 2026verified |
| Total liabilities | 9.3 m | 7.5 m | 8.0 m | 15.5 m | 21.4 m | 16.3 m | SEC (XBRL)· 15 Apr 2026verified |
| Equity | -9.4 m | 8.9 m † | 9.3 m † | -5.6 m † | -18.6 m | -15.3 m | SEC (XBRL)· 19 Aug 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -21.3 m | -14.7 m | -14.0 m | -10.2 m | -7.3 m | -4.8 m | SEC (XBRL)· 15 Apr 2026verified |
| Capex | 91.1 k | 0 | 102.7 k | 14.1 k | 3.2 k | — | SEC (XBRL)· 11 Jul 2025verified |
| Free cash flow | -21.4 m ≈ | -14.7 m ≈ | -14.1 m ≈ | -10.2 m ≈ | -7.3 m ≈ | — | SEC (XBRL)· 15 Apr 2026derived |
| Investing cash flow | -768.6 k | 0 | -102.7 k | -14.1 k | -3.2 k | — | SEC (XBRL)· 11 Jul 2025verified |
| Financing cash flow | 22.5 m | 19.0 m | 14.4 m | 6.1 m | 7.5 m | 5.1 m | SEC (XBRL)· 15 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.2 m USD
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -53,856.5% | 0 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -84.1% | 0 (on a fixed band) | 33% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -5.7x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 0.1x | 0 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Endovia Health Sciences, Inc. (EDVA). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 73.1 k USD in 2025; YoY growth -90.9%; net margin -53,856.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -53,856.5%
- Revenue CAGR 3Y: -84.1%
- Interest coverage: -5.7x
- Current ratio: 0.1x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Beverages (SIC 2080) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| KOCoca Cola Co | 412.1 bn | 28.2 | 42.6% | 28.7% | +1.9% | +31% / +64% |
| DEODIAGEO plc | 237.6 bn | 92.4 | 24.0% | 9.1% | +0.3% | +7% / −30% |
| PEPPepsico Inc | 194.1 bn | 18.7 | 50.1% | 10.8% | +2.3% | −4% / −15% |
| KDPKeurig Dr Pepper Inc. | 50.1 bn | 37.2 | 5.7% | 7.1% | +8.2% | +32% / +17% |
| BF-ABrown Forman Corp | 14.9 bn | 20.3 | 18.1% | 18.4% | −1.2% | +10% / −48% |
| PRMBPrimo Brands Corp | 7.6 bn | 79.4 | 3.2% | 1.5% | +29.3% | +34% / +46% |
| COCOThe Vita Coco Company, Inc. | 3.7 bn | 32.9 | 32.0% | 15.7% | +18.2% | +23% / +133% |
| WESTWestrock Coffee Company | 1.0 bn | — | — | -4.9% | +39.8% | +138% / +13% |
| BUDABuda Juice, Inc. | 83.2 m | 34.5 | 19.3% | 17.1% | +11.8% | unavailable / unavailable |
| SRXHSRX Global Inc. | 18.0 m | — | -70.8% | -254.8% | −81.3% | −96% / −100% |
| WVVIWillamette Valley Vineyards, Inc. | 8.3 m | — | -3.3% | -5.9% | −6.5% | −37% / −68% |
| YHCLQR House Inc. | 2.9 m | 0.2 | -88.2% | -1,589.2% | −37.4% | −98% / −100% |
| IPSTIp Strategy Holdings, Inc. | 2.3 m | — | -2,713.2% | -2,064.0% | +20.4% | −98% / unavailable |
| EDVAEndovia Health Sciences, Inc. | 1.2 m | — | — | -53,856.5% | −90.9% | −96% / −100% |
| BRCCBRC Inc. | 903.4 k | — | -14.2% | -1.5% | +1.7% | −23% / −77% |
| IBGInnovation Beverage Group Limited | 593.4 k | — | — | -223.4% | −5.1% | −94% / unavailable |
| ABEVAmbev S.A. | — | — | 16.6% | 17.6% | −1.4% | +9% / +1% |
| STZConstellation Brands, Inc. | — | — | 23.9% | 20.9% | −10.5% | +7% / −40% |
1- and 3-year price returns: for EDVA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Endovia Health Sciences (formerly Splash Beverage Group) is moving from alcoholic beverages to a cannabinoid-based health sciences platform after sales effectively stopped in 2025. Net revenue of about 0.44 million USD in fiscal 2025 and a net loss of about 25.2 million USD show the scale of the liquidity problems the company is trying to overcome.1
SWOT
Strengths
- The company holds an exclusive worldwide license for a cannabinoid pharmaceutical product, extended to veterinary use.3
- Operating costs fell significantly in the first half of 2026, making the cost structure more efficient.3
- Interim management has experience building and commercialising businesses in the cannabinoid industry.2
Weaknesses
Opportunities
Risks
- Going concernhigh
The auditors warned that liquidity raises substantial doubt about the company's ability to operate over the next twelve months.1
- Exchange listinghigh
The company failed to meet the stockholders' equity requirement, and there is a risk of delisting from NYSE American if the situation is not remedied.1
- Dilution from financingmedium
Issuing shares to fund operations could significantly reduce the value of existing shares.1
- Dependence on a single productmedium
The new strategy depends on the CannEpil license, and losing it could halt development projects.3
- Litigation over Series Clow
The seller of the Costa Rica water assets could challenge the cancellation of the Series C shares, creating legal costs.1
Investment thesis
What would need to be true (bull case)
- If the CannEpil license reaches regulatory approvals and international sales, the company could fundamentally change its revenue profile.
- Cost reductions show management can control expenses, which could extend financial runway.
- If veterinary and pharmaceutical partnerships advance, the company could attract investors interested in the cannabinoid niche.
What would break the thesis
- The company has no stable revenue, and reliance on dilutive financing could seriously hurt the value of existing shares.
- If financing is not secured or the equity requirement is not fixed, the company could be delisted or forced to halt operations.
- The new strategy is at an early stage, and regulatory approvals and commercialisation could be delayed or may not materialise.
What to watch
- Effect of the name and ticker change on NYSE AmericanAugust 2026
- Progress of the veterinary collaboration with Lupvindol Biosciences2027
- Confirmation of the financing needed for operations and NYSE American compliancenext 10-K
- First CannEpil sales through international partnersQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The Nevada company was active in beverages, with the Chispo tequila brand as its main product. According to the annual report, it generated no revenue from March 2025 until March 2026 due to a lack of working capital.1 In the second half of 2026 management repositioned the company toward cannabinoid and pharmaceutical products, with an exclusive worldwide license for CannEpil, aimed at drug-resistant epilepsy, and extensions into veterinary use.23
Production is outsourced: Chispo tequila is made in Mexico under terminable co-packing arrangements, and the company has one full-time employee, its President.1 The name and NYSE American ticker change is announced for August 24, 2026.3
Financing has relied on convertible notes and an equity line, and the annual report includes a going-concern doubt paragraph from the auditors.12
Segments
Alcoholic beverages (legacy)
The traditional segment, centred on Chispo tequila, produced only 0.07 million USD of revenue in fiscal 2025 and was largely halted for lack of inventory capital.1 The contract with the single customer was later terminated, and the company no longer pursues Chispo sales.2
Pharmaceutical and veterinary cannabinoids
The new pillar rests on the CannEpil license, later extended to veterinary use, with a development collaboration for a veterinary product through the FDA CVM pathway.3 It is a new direction with no reported revenue so far, and its progress depends on studies and regulatory approvals.3
Market context
The alcoholic beverage market, where the company was active, is described as highly competitive, with international, national and regional producers.1 The new direction targets cannabinoid pharmaceutical and wellness markets regulated at federal level in the US and subject to each country's legal conditions.23
The cannabinoid product market is less standardised, and commercialising pharmaceutical products requires studies, FDA approvals and dedicated distribution, which could delay market entry.3
Trends
- Cannabinoid regulationmixed
The regulatory framework for cannabinoid products could open access to patients and pharmaceutical partners if FDA approvals are obtained.3
- Capital pressure on small companiesheadwind
Lack of capital stopped sales and forced the company to rely on dilutive financing, which limits its ability to invest in new programmes.1
- Cost reductiontailwind
Cuts in overhead and personnel costs significantly improved the operating loss in the first half of 2026, but have not yet changed the revenue model.3
- Consolidation in cannabis and wellnessmixed
Interest in acquisitions and partnerships in cannabis can create opportunities, but also competition for the same assets.2
Competitive position
The alcoholic beverage market is dominated by large producers and regional distributors, with competition based on price, promotion and distribution.1 For the new direction, competition comes from pharmaceutical and cannabinoid companies developing epilepsy and veterinary products.3
The company notes the risk that competitors market similar products, which could reduce the market share of CannEpil if development succeeds.3
- Independent alcoholic beverage producers
Traditional tequila and spirits competitors, described as numerous at international, national and regional level.1
- Cannabinoid and wellness companies
Producers and distributors of federally compliant cannabinoid products with whom the company could compete in wellness.2
- Pharmaceutical firms with epilepsy products
Companies developing treatments for refractory epilepsy, a field where similar products could emerge, according to the report's warnings.3
- Veterinary medicine partners
Animal health companies that could develop competing products for companion-animal oncology and chronic pain.3
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Proxy statement02 Nov 2026
- Current report27 Oct 2026Material agreement · Financial statements and exhibits
- Current report15 Oct 2026Material agreement · Financial statements and exhibits
- Current report06 Oct 2026Item 3.02
- Proxy statement05 Oct 2026
- Current report05 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report24 Sept 2026Material agreement · Item 3.02 · Financial statements and exhibits
- Current report22 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report31 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Current report28 Aug 2026Item 3.02
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Endovia Health Sciences, Inc. · 15 Apr 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Endovia Health Sciences, Inc. · 19 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Endovia Health Sciences, Inc. · 20 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.